Carlsmed, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-06-26. It has amended it 1 time. It filed its final prospectus on 2025-07-24, at a public offering price of $15.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “CARL.”From the 424B4 filed 2025-07-24
Shares offered
This is an initial public offering of shares of common stock by Carlsmed, Inc. We are offering 6,700,000 shares of common stock, par value $0.00001 per share (“common stock”).From the 424B4 filed 2025-07-24
Offering price
The initial public offering price is $15.00 per share.From the 424B4 filed 2025-07-24
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to support the commercialization of the aprevo Technology Platform and expand and improve our product offerings, including approximately $24.7 million to support our increased sales and marketing efforts, approximately $45.9 million to fund our research and development activities to advance the aprevo Technology Platform, including the continued development of the aprevo Technology Platform for use in cervical spine fusion surgeries, and the remainder for working capital and general corporate purposes.From the 424B4 filed 2025-07-24
Revenue
For the years ended December 31, 2024 and 2023, we recognized revenue of $27.2 million and $13.8 million, respectively, representing year-over-year growth of 97.2%.From the S-1/A filed 2025-07-15
Net loss or income
For the year ended December 31, 2024, we recognized a gross margin of 73.8% and a net loss of $24.3 million, compared to a gross margin of 71.9% and a net loss of $18.9 million for the year ended December 31, 2023.From the S-1/A filed 2025-07-15
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-06-26 | Registration statement filed | S-1 |
| 2025-07-15 | Registration statement amended | S-1/A |
| 2025-07-24 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Carlsmed, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.